Researchers are working overtime to develop therapies that, for the first time, specifically target Guillain-Barré Syndrome.

In lieu of flowers, please consider a donation to the GBS/CIDP Foundation International or to Penn State St. Joseph Medical Center. Online condolences can be made at maestumpfuneralhome.com ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

The phase IIb study is evaluating batoclimab in CIDP patients whose disease had worsened during standard-of-care treatment. CIDP is a rare autoimmune neurological disorder that causes progressive ...

Immunovant, Inc. will host an investor webcast on March 19 to discuss Phase 3 study results for batoclimab in MG and CIDP. Immunovant, Inc. announced that it will hold an investor webcast on March ...

Guillain-Barré Syndrome (GBS) is a rare neuromuscular condition that can cause rapid paralysis. Diagnosing GBS is challenging, and misdiagnosis can lead to delayed treatment and potentially long ...

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it ...

top-line results on track for 2H’25 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; interim responder analysis anticipated in 2H’26 ...

Brian Melanson started as a Multimedia Journalist for 12 News in October 2024. A native of Norwalk, CT, Brian graduated from the University of Maryland in May 2024 with a BA in Journalism.

Darren Drake Nelson, age 53, of Edwardsville, Illinois passed away on Thursday, March 13, 2025 at Barnes Hospital in St. Louis, MO. Darren was born on April 21, 1971 in St. Louis, a son of Gary L. and ...